On Nov 01, major Wall Street analysts update their ratings for $Merck & Co (MRK.US)$, with price targets ranging from $110 to $150.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and adjusts the target price from $130 to $123.
BofA Securities analyst Charlie CY Yang maintains with a buy rating, and sets the target price at $120.
Wells Fargo analyst Mohit Bansal maintains with a hold rating, and adjusts the target price from $125 to $110.
BMO Capital analyst Evan Seigerman maintains with a buy rating, and maintains the target price at $150.
Furthermore, according to the comprehensive report, the opinions of $Merck & Co (MRK.US)$'s main analysts recently are as follows:
The recent quarterly report underscored persistent uncertainties surrounding Gardasil and the market in China as we approach 2024. Following the third-quarter earnings surpassing expectations and guidance being largely sustained, estimates have been adjusted accordingly.
Merck's Q3 results exhibited a modest surpass in both revenue and earnings, however, the stock experienced a slight decline as the company fine-tuned its revenue outlook and reduced its EPS projections to account for charges associated with previous acquisitions. While revenue forecasts for 2024 remain largely unaltered and EPS estimates show a minor increase, projections for 2025 have been adjusted downwards due to anticipated reductions in Gardasil sales and heightened operational expenditures.
Merck's adjustment of its Gardasil expectations represents a positive direction. However, the introduction of new investments may require a change in narrative, and it's uncertain if Winrevair alone will be sufficient to initiate this shift, according to an analyst's research note.
Here are the latest investment ratings and price targets for $Merck & Co (MRK.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
